China’s CanSino recruits over 20,000 people for Covid vaccine trials

Published December 22, 2020
In this file photo, vials of a Covid-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China. — Reuters
In this file photo, vials of a Covid-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China. — Reuters

BEIJING: China’s CanSino Biologics Inc has recruited over 20,000 participants for late-stage human trials overseas for its coronavirus vaccine, a health official said on Monday.

The candidate, known as Ad5-nCoV or Convidecia, which CanSinoBIO is jointly developing with a research institute backed by the Chinese military, is among the five vaccines China has moved into Phase 3 clinical trials to test their efficacy.

“As for now, the number of recruited participants has exceeded 20,000 people, and the progress is relatively fast,” Zheng Zhongwei, an official at China’s National Health Commission, told a press conference.

Pakistan among states where participants are being listed

Phase 3 trials for CanSinoBIO’s candidate, which are planned to involve 40,000 participants in total, have begun enrolling participants in Pakistan, Russia, Mexico and Chile, the latest clinical trial registration data showed. The candidate also has trials lined up in Argentina and has secured a supply deal with Mexico.

The one-dose vaccine had been given to about 40,000-50,000 people in emergency use since it obtained approval for use in military personnel in June, CanSinoBIO Chief Executive Yu Xuefeng said in an industrial event on Nov 28.

A vaccine developed by Chinese Academy of Medical Sciences could start Phase 3 clinical trial soon, Zheng said on Monday, without specifying where it will be tested.

Published in Dawn, December 22nd, 2020

Opinion

Editorial

Afghan outreach
Updated 11 Jan, 2025

Afghan outreach

Islamabad should stress stronger counterterrorism measures, yet also engage the Taliban high command in Kandahar as well as politicians in Kabul.
Fragile recovery
11 Jan, 2025

Fragile recovery

STATE Bank Governor Jameel Ahmed appears to be quite optimistic over recent economic gains. That is not unusual;...
Destination Europe
11 Jan, 2025

Destination Europe

THE country’s aviation authorities can rest a little easy. After a four-year banishment from European skies,...
E-governance
Updated 10 Jan, 2025

E-governance

Wishing for a viable e-governance system seems like a pipe dream when stable internet connectivity is not guaranteed.
Khuzdar rampage
Updated 10 Jan, 2025

Khuzdar rampage

Authorities must explain how terrorists were able to commandeer the area for eight hours.
Beyond wheelchairs
10 Jan, 2025

Beyond wheelchairs

THE KP government’s Rs370m assistance programme for persons with disabilities is a positive step, not only in ...